Abstract
γδ T cells can be an option for adoptive immunotherapy of cancer. The major obstacle to clinical application of γδ T cells is their low number and lack of a reliable method to expand them consistently and efficiently. We were able to expand γδ T cells with high purity in all donors regardless of their starting repertoire of γδ T cells. These ex vivo expanded γδ T cells are in early differentiation stage, can efficiently kill various tumors and inhibit growth of human lung cancer xenografts. This new approach for ex vivo expansion of human γδ T cells will open new horizons for clinical use of these cells.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
